TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34487086
Drug: 2-hour Oral
Normalized name: dextroamphetamine 2 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour Oral Glucose Tolerance Test (OGTT)
Study: 33934519
Drug: Durlobactam 4
Normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durlobactam 4 g (supratherapeutic dose)
Study: 33934519
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus moxifloxacin 400 mg (open-label)
Study: 33313732
Drug: Low-dose chiropractic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chiropractic care (1 to 5 visits)
Study: 33313732
Drug: Higher-dose chiropractic
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose chiropractic care (8 to 12 visits)
Study: 33313732
Drug: Monthly chiropractic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly chiropractic chronic pain management for 10 months
Study: 34086481
Drug: Induction neoadjuvant
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction neoadjuvant hormonal therapy (HT) with fulvestrant 500 mg (with or without goserelin)
Study: 34086481
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg plus palbociclib
Study: 34086481
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg plus placebo
Study: 35897310
Drug: Lactiplantibacillus plantarum
Normalized name: Lactiplantibacillus plantarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactiplantibacillus plantarum SNK12 (50 mg/day)
Study: 35897310
Drug: Lactiplantibacillus plantarum
Normalized name: Lactiplantibacillus plantarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactiplantibacillus plantarum SNK12 (150 mg/day)
Study: 33782036
Drug: Ramipril (1.25-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25-10 mg/d)
Study: 33782036
Drug: Non-RAS inhibition
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-RAS inhibition therapy
Study: 34529065
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation at hospital admission
Study: 34529065
Drug: Standard, physician-acquired
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, physician-acquired medication history (Control)
Study: 33636242
Drug: Microneedle patch
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle patch plus 5% topical lidocaine
Study: 33636242
Drug: Patch without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch without microneedles plus 5% topical lidocaine
Study: 35535436
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (VAR, BUP, NRT)
Study: 32425111
Drug: Low-Na solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Na solution (112 mmol/L Na and 2% glucose)
Study: 32425111
Drug: Standard-Na solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Na solution (133 mmol/L Na and 1.5% glucose)
Study: 34802925
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration
Study: 33813580
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: 33385299
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg twice daily for 6 months
Study: 32218417
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment complex (dietary and proton pump inhibitor drugs)
Study: 615245085
Drug: Collagenase Clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium histolyticum (CCH) intralesional injection
Study: 32805428
Drug: Lipid-containing tear
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-containing tear supplement (Systane Complete)
Study: 34700598
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with ISBT boost (initial dose 50Gy with IMRT followed by 24.5Gy dose in 12 fractions)
Study: 32130284
Drug: Anorganic xenograft
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorganic xenograft added at the time of flapless, one-stage placement of a sloped-platform implant
Study: 33453095
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation (TF) - Product A
Study: 33972256
Drug: Etesevimab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etesevimab (2.5 to 50 mg/kg)
Study: 32852530
Drug: Fingolimod, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod, 0.25 mg
Study: 32852530
Drug: Glatiramer acetate,
Normalized name: Glatiramer Acetate, 20 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatiramer acetate, 20 mg
Study: 32473673
Drug: elexacaftor plus
Normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elexacaftor plus tezacaftor plus ivacaftor combination regimen
Study: 33591125
Drug: Subacromial hyaluronate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subacromial hyaluronate injection (2 mL, 20 mg, hyaluronate 1% (500 to 700 kDa))
Study: 35437111
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (CC‐486)
Study: 33560633
Drug: Wrist actigraphy
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wrist actigraphy for hourly activity counts
Study: 36055295
Drug: Dolutegravir-based ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir-based ART (5 mg dispersible dolutegravir dosed according to WHO weight bands)
Study: 36055295
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (mainly protease inhibitor-based ART)
Study: 33306506
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) intake (g/d)
Study: 33306506
Drug: Isoflavones intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones intake (mg/d)
Study: 33306506
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake (mg/d)
Study: 33306506
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake (mg/d)
Study: 33306506
Drug: Carbohydrates intake
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrates intake among rs738409 G-allele carriers
Study: 33306506
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs intake among rs738409 G-allele carriers
Study: 33306506
Drug: Isoflavones intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones intake among rs738409 G-allele carriers
Study: 33306506
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake among rs738409 G-allele carriers
Study: 33306506
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake among rs738409 G-allele carriers
Study: 35760720
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg monthly)
Study: 33030020
Drug: Topical 1:1000
Normalized name: thimerosal topical 1:1000 topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1:1000 epinephrine
Study: 33030020
Drug: Topical 1:10
Normalized name: thimerosal topical 1:1000 topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1:10 000 epinephrine
Study: 35065636
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg of curcuminoid + 5 mg piperine)
Study: 36370716
Drug: q3EC-P (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: q3EC-P (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks followed by paclitaxel 175 mg/m2 every 3 weeks)
Study: 36370716
Drug: q3FEC-P (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: q3FEC-P (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 every 3 weeks followed by paclitaxel 175 mg/m2 every 3 weeks)
Study: 36370716
Drug: q2EC-P (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: q2EC-P (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks followed by paclitaxel 175 mg/m2 every 2 weeks)
Study: 36370716
Drug: q2FEC-P (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: q2FEC-P (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 every 2 weeks followed by paclitaxel 175 mg/m2 every 2 weeks)
Study: 32556496
Drug: Literature-mining approach
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature-mining approach analyzing cancer immunotherapy publications
Study: 32556496
Drug: Research topics
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research topics in cancer immunotherapy
Study: 35512165
Drug: Arm sling
Normalized name: Universal Arm Sling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm sling with kinesiotaping therapy (group K)
Study: 35886615
Drug: Weekly educational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly educational newsletters (Control)
Study: 33151961
Drug: miR-21 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: miR-21 inhibitor
Study: 36451359
Drug: Soft Touch
Normalized name: Soft Touch Blue
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soft Touch Training (STT) - guided soft brushing of selected skin regions, 15-minute daily sessions for 4 weeks
Study: 36451359
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation (PMR) - guided tensing and relaxing of selected muscle regions, 15-minute daily sessions for 4 weeks
Study: 32248637
Drug: One-session exposure
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session exposure therapy
Study: 32248637
Drug: Three-session exposure
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-session exposure therapy
Study: 34605397
Drug: Preprocedural risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural risk score model based on five variables: age > 75 years, serum creatinine level ≥ 1.5 mg/dL, diabetes mellitus, hypotension, acute myocardial infarction.
Study: 32703244
Drug: Partial Tinnitus
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Tinnitus Retraining Therapy (Partial TRT)
Study: 33561141
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of 0.9% sodium chloride (239 women)
Study: 32459919
Drug: Remdesivir for
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir for 5 days (200 mg on day 1, 100 mg once daily thereafter)
Study: 32459919
Drug: Remdesivir for
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir for 10 days (200 mg on day 1, 100 mg once daily thereafter)
Study: 34256041
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training (RET) for 16 weeks, performed twice weekly at low intensity
Study: 32178953
Drug: Extraluminal bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extraluminal bronchial blocker (BB) for one-lung ventilation (OLV)
Study: 37031887
Drug: Sacubitril/valsartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (200 mg twice daily)
Study: 35458138
Drug: Aqueous cinnamon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cinnamon extract (6 g/100 mL)
Study: 35458138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral glucose tolerance test only)
Study: 32565450
Drug: One-to-one befriending
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-to-one befriending by volunteers for people with ID (weekly visits for 6 months)
Study: 33733588
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy after radical hysterectomy
Study: 35903950
Drug: l-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (8 grams)
Study: 32130359
Drug: Azithromycin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (administered orally for 7 days)
Study: 32130359
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered orally for 7 days)
Study: 33753669
Drug: 0.145% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.145% sodium fluoride gel in a custom tray during sleep
Study: 33640423
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy (IMRT)
Study: 32053276
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIg)
Study: 33386662
Drug: Biological risk
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological risk score
Study: 33386662
Drug: Biological score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological score + predefined clinical score
Study: 35371277
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation treatment
Study: 33779742
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation therapy (TROG 01.04)
Study: 33779742
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy omission (Dutch TME)
Study: 32692270
Drug: High NK
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NK cell count (≥184 × 10^6 cells/L) at baseline
Study: 32692270
Drug: High NK
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NK cell count (≥184 × 10^6 cells/L) before cycle 2
Study: 35889947
Drug: Peanut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut group (35 g of lightly salted dry-roasted peanuts prior to two main meals per day)
Study: 36763358
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg
Study: 35213496
Drug: Deep neuromuscular
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular block (NMB) with continuous infusion of rocuronium (0.5-1.0 mg kg⁻¹ h⁻¹)
Study: 35213496
Drug: Moderate neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular block (NMB) with continuous infusion of rocuronium (0.1-0.5 mg kg⁻¹ h⁻¹)
Study: 35004776
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression plus metformin (500 mg twice daily)
Study: 35004776
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression plus empagliflozin (25 mg once daily)
Study: 32144074
Drug: HBV-AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-AS04 vaccine (4 doses of 20 mcg each by intramuscular route)
Study: 32144074
Drug: HBV-AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-AS04 vaccine
Study: 36245339
Drug: GP-delivered medication
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP-delivered medication review intervention
Study: 32791589
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine for 2 years
Study: 32791589
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo and conventional drug treatment)
Study: 36199765
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug therapy and small incision reduction and suture
Study: 32274665
Drug: Treatment-induced symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced symptoms (vaginal dryness, sleep disturbances, bone or joint pain) at 6 months
Study: 33188417
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain wheat (WGW) intervention (98 g/d)
Study: 33188417
Drug: Refined wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined wheat (RW) intervention (98 g/d)
Study: 33883461
Drug: Combination BP
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination BP therapy with perindopril and indapamide
Study: 32802868
Drug: SL implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL implants (implants with an augmented depth of the threads)
Study: 32802868
Drug: SY implants
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SY implants (implants with standard threads)
Study: 32802868
Drug: Both SL
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SL and SY implants
Study: 32384160
Drug: Systemic patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic patient-controlled analgesia (PCA) or regional analgesic techniques
Study: 35970671
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 25 mL of bupivacaine plus 0.5 μg/kg of dexmedetomidine
Study: 35970671
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous analgesia with a 0.7 μg/kg dexmedetomidine bolus and a 0.3 μg/kg infusion
Study: 33025616
Drug: Fenugreek extract
Normalized name: Fenugreek extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek extract (FHE) 250 mg × 2/day for 42 days
Study: 34017263
Drug: Norepinephrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine treatment
Study: 33852919
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w (Mw) 0.3 mL/d intradermally for 3 days
Study: 35639720
Drug: Citicoline 1gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1gm BD intravenously for three days, followed by oral citicoline 1gm BD for 39 days.
Study: 35639720
Drug: Placebo (100ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100ml intravenous normal saline for three days, followed by multivitamin tablet BD for 39 days).
Study: 33147257
Drug: G-CSF post-ASCT
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF post-ASCT
Study: 33147257
Drug: Avoided G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoided G-CSF post-ASCT
Study: 33147257
Drug: Avoided G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoided G-CSF and added corticosteroid prophylaxis post-ASCT
Study: 33147257
Drug: G-CSF avoidance
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF avoidance plus corticosteroids
Study: 36116756
Drug: Mindfulness-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based interventions (up to 3 sequential interventions based on non-response)
Study: 33751297
Drug: Overall (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (50 implants)
Study: 32134114
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A virus vaccine (HA‐L)
Study: 34838132
Drug: Intravenous thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thyroxine for at least 12 hours
Study: 32424949
Drug: Xylazine continuous
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine continuous rate infusion (CRI) at 1 mg/kg/hr for 2, 4, and 6 hours after an initial bolus of 0.5 mg/kg
Study: 32424949
Drug: Xylazine continuous
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine continuous rate infusion (CRI)
Study: 35260787
Drug: tolcapone (COMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (COMT inhibitor)
Study: 35468752
Drug: Contoura treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contoura treatment
Study: 35468752
Drug: Custom‐Q treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom‐Q treatment
Study: 34241629
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg orally once daily on days 1 to 21) plus SOX (S‐1: 40‐60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles
Study: 33326878
Drug: Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Care Therapy (SCT)
Study: 34925003
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) prescriptions
Study: 35492074
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Ketamine (Mor + Ket)